BIO (Bio-Rad Laboratories, Inc.) Gross Margin

BIO (Bio-Rad Laboratories, Inc.) - company brandmark

Bio-Rad Laboratories (BIO) supplies equipment and tests for the Life Science B2B segment, utilizing a profitable consumables business model. The delivery of sensitive components relies on a costly cold chain system. The gross margin demonstrates capital management efficiency, while 52.20 captures the current state of the parameter. Business stability is ensured by consistent demand for diagnostics with a moderate dependence on government funding.

BIO - bio-rad.com Return on Gross Profit over the range 07/04/2022 - 11/19/2026

Financial and market metric breakdowns for Bio-Rad Corp (BIO)

- stock price and consensus target price:
- business market valuation indicators:
Fundamental valuation:Bio-Rad Laboratories, Inc., BIO
Finished products of Bio-Rad Laboratories Inc

Gross margin measures production efficiency by determining the portion of revenue remaining after direct product costs, which allows for an assessment of the assets' fundamental pricing power. The stable gross margin level of Bio-Rad Laboratories (BIO) confirms the high value of its closed ecosystem of diagnostic solutions, where the integration of hardware and consumables minimizes customer churn and guarantees sustainable operating profitability.